East China occupy 40% of China's pharmaceutical circulation market

The business community reported on September 21 that the National Outline for the Development of Drug Distribution Industry (2011-2015) is likely to meet people in November of this year, and the core of the “planning” is to improve the pharmaceutical distribution industry. The degree of concentration will result in the creation of 1-2 national pharmaceutical distribution companies with annual sales of 100 billion yuan and 20 regional pharmaceutical distribution leaders with annual sales of over 10 billion yuan by 2015.

According to Guo Fanli, a research fellow in the pharmaceutical industry of China Investment Advisors, in the pharmaceutical circulation market in China, seven major market segments are divided, including East China Market, North China Market, South China Market, Central China Market, Southwestern Market, Northeast Market, and Northwest Market. These market segments include not only the provinces under their jurisdiction but also major local pharmaceutical distribution companies, such as local pharmaceutical circulation leaders and national pharmaceutical distribution companies.

Guo Fanli pointed out that in the East China market, the provinces it contains include Shanghai, Jiangsu, Zhejiang, and Anhui. Because of its broad scope, the competition among local pharmaceutical distributors is fierce. What has to be mentioned is Shanghai Pharmaceuticals. Shanghai Pharmaceuticals itself is a national comprehensive pharmaceutical circulation leader. After the reorganization of Shanghai Pharmaceuticals, its scale is second only to Sinopharm, and its pharmaceutical distribution business accounts for 52.6% of Shanghai's market share, respectively. There is also a 16.3% market share in East China.

In the North China market, the provinces it contains include Beijing, Tianjin, Hebei, Shanxi, etc. Since it is located in the capital city of China, the competition is fierce. The national and regional pharmaceutical circulation leaders such as Sinopharm Medicine and Beijing Medicine are This began fierce competition. In the South China market, Guangdong, Hainan, and Guangxi provinces are included. In this market, the main competitors are Guangzhou Pharmaceuticals and Accord Pharmaceuticals, among which Guangzhou Pharmaceuticals ranked fifth in the Medicines Circulation 100 list in 2009.

Zhang Yanlin, research director of China Investment Consulting, pointed out that in the Central China market, the provinces it contains are Henan, Hubei, and Hunan. This includes, of course, the Jiuzhoutong Group, the largest pharmaceutical distribution company in Hubei Province, which is also the largest privately-owned pharmaceutical company in the country. enterprise. In addition, Changsha Shuanghe also actively entered the competition in the pharmaceutical circulation field. In the southwest markets, mainly Chongqing, Sichuan, Guizhou, and Yunnan, local companies such as Chongqing Pharmaceuticals and Tongjunge all have a place.

The “2010-2015 China Pharmaceutical Industry Investment Analysis and Prospect Forecast Report” released by the China Investment Advisor pointed out that from the market share held by these regional markets nationwide, due to the wide scope of the East China region, plus some historical reasons It occupies the leading position in the national pharmaceutical circulation market, its share is as high as 40%; and the North China market also has more than 20% market share. As a whole, the pharmaceutical market in the northwest market accounts for the least share of the national market, only 3%.